$175-230k
+ Equity
End-to-end medical trial solutions
Open for applications
End-to-end medical trial solutions
101-200 employees
Open for applications
$175-230k
+ Equity
101-200 employees
To bring new treatments to patients faster and more efficiently.
Clinical drug trials are lengthy and expensive, delaying the supply of vital new drugs to patients and costing lives. For Formation Bio, this is an efficiency issue - one which it hopes to solve with its end-to-end automation solution.
According to the company, its approach has teams running medical trials twice as fast and at half the cost. It's worked so well, in fact, that Formation Bio is looking to take drug development in-house.
Now a Unicorn, the company has secured heavyweights like Pfizer, Sanofi, Novartis and 23andMe as partners. Precisely how it will fare in the Big Pharma ecosystem remains to be seen, but the promise of cheaper drugs and faster innovation is certainly causing a stir in a market that has historically been resistant to both.
Kirsty
Company Specialist
Jun 2024
$372m
SERIES D
Sep 2021
$156m
SERIES C
Midtown South, New York, NY
Founders
Benjamine Liu
(CEO)Worked as a computational biologist at various Neurology departments, following a D.Phil in computational Biology and Psychiatry at Oxford. They are also an Advisor at Harvard Business School.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 10 more jobs at Formation Bio